PRIORITIZING HUMAN PHARMACEUTICALS FOR ECOLOGICAL RISKS IN THE FRESHWATER ENVIRONMENT OF KOREA

被引:18
作者
Ji, Kyunghee [1 ]
Han, Eun Jeong [2 ]
Back, Sunhyoung [3 ]
Park, Jeongim [3 ]
Ryu, Jisung [4 ]
Choi, Kyungho [5 ]
机构
[1] Yongin Univ, Dept Occupat & Environm Hlth, Yongin, South Korea
[2] Seoul Natl Univ, Grad Sch Environm Studies, Environm Planning Inst, Seoul, South Korea
[3] Soonchunhyang Univ, Dept Environm Sci, Asan, South Korea
[4] Natl Inst Chem Safety, Accid Prevent & Assessment Div, Daejeon, South Korea
[5] Seoul Natl Univ, Grad Sch Publ Hlth, Seoul, South Korea
关键词
Pharmaceuticals; Environmental risk assessment; Prioritization; PhATE; PERSONAL CARE PRODUCTS; SURFACE WATERS; ANTIBIOTICS; EXPOSURE; RANKING; MICROPOLLUTANTS; TOXICITY; IMPACTS;
D O I
10.1002/etc.3233
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Pharmaceutical residues are potential threats to aquatic ecosystems. Because more than 3000 active pharmaceutical ingredients (APIs) are in use, identifying high-priority pharmaceuticals is important for developing appropriate management options. Priority pharmaceuticals may vary by geographical region, because their occurrence levels can be influenced by demographic, societal, and regional characteristics. In the present study, the authors prioritized human pharmaceuticals of potential ecological risk in the Korean water environment, based on amount of use, biological activity, and regional hydrologic characteristics. For this purpose, the authors estimated the amounts of annual production of 695 human APIs in Korea. Then derived predicted environmental concentrations, using 2 approaches, to develop an initial candidate list of target pharmaceuticals. Major antineoplastic drugs and hormones were added in the initial candidate list regardless of their production amount because of their high biological activity potential. The predicted no effect concentrations were derived for those pharmaceuticals based on ecotoxicity information available in the literature or by model prediction. Priority lists of human pharmaceuticals were developed based on ecological risks and availability of relevant information. Those priority APIs identified include acetaminophen, clarithromycin, ciprofloxacin, ofloxacin, metformin, and norethisterone. Many of these pharmaceuticals have been neither adequately monitored nor assessed for risks in Korea. Further efforts are needed to improve these lists and to develop management decisions for these compounds in Korean water. (C) 2015 SETAC
引用
收藏
页码:1028 / 1036
页数:9
相关论文
共 53 条
  • [1] Screening analysis of human pharmaceutical compounds in US surface waters
    Anderson, PD
    D'Aco, VJ
    Shanahan, P
    Chapra, SC
    Buzby, ME
    Cunningham, VL
    Duplessie, BM
    Hayes, EP
    Mastrocco, FJ
    Parke, NJ
    Rader, JC
    Samuelian, JH
    Schwab, BW
    [J]. ENVIRONMENTAL SCIENCE & TECHNOLOGY, 2004, 38 (03) : 838 - 849
  • [2] [Anonymous], 2011, TECHNICAL GUIDANCE D, DOI DOI 10.2779/43816
  • [3] Human pharmaceuticals in surface waters implementation of a prioritization methodology and application to the French situation
    Besse, Jean-Philippe
    Garric, Jeanne
    [J]. TOXICOLOGY LETTERS, 2008, 176 (02) : 104 - 123
  • [4] Pharmaceuticals and Personal Care Products in the Environment: What Are the Big Questions?
    Boxall, Alistair B. A.
    Rudd, Murray A.
    Brooks, Bryan W.
    Caldwell, Daniel J.
    Choi, Kyungho
    Hickmann, Silke
    Innes, Elizabeth
    Ostapyk, Kim
    Staveley, Jane P.
    Verslycke, Tim
    Ankley, Gerald T.
    Beazley, Karen F.
    Belanger, Scott E.
    Berninger, Jason P.
    Carriquiriborde, Pedro
    Coors, Anja
    DeLeo, Paul C.
    Dyer, Scott D.
    Ericson, Jon F.
    Gagne, Francois
    Giesy, John P.
    Gouin, Todd
    Hallstrom, Lars
    Karlsson, Maja V.
    Larsson, D. G. Joakim
    Lazorchak, James M.
    Mastrocco, Frank
    McLaughlin, Alison
    McMaster, Mark E.
    Meyerhoff, Roger D.
    Moore, Roberta
    Parrott, Joanne L.
    Snape, Jason R.
    Murray-Smith, Richard
    Servos, Mark R.
    Sibley, Paul K.
    Straub, Juerg Oliver
    Szabo, Nora D.
    Topp, Edward
    Tetreault, Gerald R.
    Trudeau, Vance L.
    Van Der Kraak, Glen
    [J]. ENVIRONMENTAL HEALTH PERSPECTIVES, 2012, 120 (09) : 1221 - 1229
  • [5] Brooks B., 2012, Human Pharmaceuticals in the Environment, V4, P1
  • [6] Canadian Pharmacists Association, 2011, THER CHOIC, P1653
  • [7] Preliminary risk assessment database and risk ranking of pharmaceuticals in the environment
    Cooper, Emily R.
    Siewicki, Thomas C.
    Phillips, Karl
    [J]. SCIENCE OF THE TOTAL ENVIRONMENT, 2008, 398 (1-3) : 26 - 33
  • [8] Predicting concentrations of trace organic compounds in municipal wastewater treatment plant sludge and biosolids using the PhATE™ model
    Cunningham, Virginia L.
    D'Aco, Vincent J.
    Pfeiffer, Danielle
    Anderson, Paul D.
    Buzby, Mary E.
    Hannah, Robert E.
    Jahnke, James
    Parke, Neil J.
    [J]. INTEGRATED ENVIRONMENTAL ASSESSMENT AND MANAGEMENT, 2012, 8 (03) : 530 - 542
  • [9] Human health risk assessment of carbamazepine in surface waters of North America and Europe
    Cunningham, Virginia L.
    Perino, Christopher
    D'Aco, Vincent J.
    Hartmann, Andreas
    Bechter, Rudolf
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2010, 56 (03) : 343 - 351
  • [10] Prioritizing Contaminants of Emerging Concern for Ecological Screening Assessments
    Diamond, Jerome M.
    Latimer, Henry A., II
    Munkittrick, Kelly R.
    Thornton, Kent W.
    Bartell, Steven M.
    Kidd, Karen A.
    [J]. ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY, 2011, 30 (11) : 2385 - 2394